These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24892422)

  • 21. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia.
    Demeter J; Hamed A; László S; Suvajdzic N; Aigner S; Börner B; Staiger C
    Transfus Med; 2023 Apr; 33(2):165-173. PubMed ID: 36448274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
    Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
    Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.
    Shahgholi E; Vosough P; Sotoudeh K; Arjomandi K; Ansari S; Salehi S; Faranoush M; Ehsani MA
    Indian J Pediatr; 2008 Dec; 75(12):1231-5. PubMed ID: 19190878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience.
    Alioglu B; Ercan S; Tapci AE; Zengin T; Yazarli E; Dallar Y
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):505-9. PubMed ID: 23470649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura.
    Erduran E; Aslan Y; Gedik Y; Orhan F
    Turk J Pediatr; 2003; 45(4):295-300. PubMed ID: 14768792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pre-delivery medication treatment on delivery outcome in patients with primary immune thrombocytopenia: a cohort study.
    Xu X; Liang MY; Zhao LR; Wang JL; Zhang XH
    Platelets; 2024 Dec; 35(1):2380366. PubMed ID: 39087677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.
    Blanchette V; Imbach P; Andrew M; Adams M; McMillan J; Wang E; Milner R; Ali K; Barnard D; Bernstein M
    Lancet; 1994 Sep; 344(8924):703-7. PubMed ID: 7915773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
    Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
    Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
    Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
    Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
    J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.
    Warrier I; Bussel JB; Valdez L; Barbosa J; Beardsley DS
    J Pediatr Hematol Oncol; 1997; 19(3):197-201. PubMed ID: 9201140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.
    Gereige RS; Barrios NJ
    P R Health Sci J; 2000 Mar; 19(1):15-8. PubMed ID: 10761200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
    Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
    J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
    Tarantino MD; Madden RM; Fennewald DL; Patel CC; Bertolone SJ
    J Pediatr; 1999 Jan; 134(1):21-6. PubMed ID: 9880444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.
    Kumar M; Vik TA; Johnson CS; Southwood ME; Croop JM
    Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
    Ramadan KM; El-Agnaf M
    Clin Lab Haematol; 2005 Aug; 27(4):267-9. PubMed ID: 16048495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.